IVBM All Coverage

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

In part 2 of our interview with Karen Winkfield, MD, PhD, she speaks to the importance of ensuring health care accessibility and of knowing that the health care system is not a one-size-fits-all arrangement.

Tiago Biachi, MD, PhD, highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, while emphasizing the importance of lifestyle factors in prevention and recurrence.

In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.

Edgardo S. Santos, MD, FACP, FASCO, emphasized the need to eliminate the stigma around smoking in lung cancer, highlighted the importance of early detection and discussed how advances in precision medicine, genomic studies, and targeted therapies have improved patient outcomes and reduced health care costs.

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks on his hoped-for top health care priorities under the incoming administration.

Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient concerns about technology understanding and insurance coverage, as well as the reliance on traditional tissue biopsies, emphasizing the benefits of combining liquid and tissue biopsies to improve treatment outcomes and clinical trial eligibility.

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.

In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.

Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.

Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and managed in the long term, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, less invasive diagnostics, with key applications in early detection, predictive biomarker identification, treatment response monitoring, resistance mechanism assessment, and minimal residual disease detection.

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.

While treatment options may be fairly straightforward for high-risk patients with polycythemia vera, it’s less clear for patients who are considered low risk, explained Jennifer Vaughn, MD.

There are a number of considerations both in the short and long term to consider when making treatment decisions for younger patients with myeloproliferative neoplasms (MPNs).

The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care delivery, addressing obesity, and tackling health inequities across various disciplines.

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature.

Demonstrating improvements in patient quality of life using patient-reported outcomes are important for treatments for myeloproliferative neoplasms (MPNs), said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.

Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.

At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases.

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).